SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF
Launched by UNIVERSITY OF PALERMO · Jun 2, 2024
Trial Information
Current as of February 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
All enrolled patients will undergo a comprehensive physical examination post-randomization. This examination will involve a meticulous assessment of congestive heart failure (CHF) indicators, encompassing the measurement of bodyweight (BW) (taken in the morning before breakfast), supine and standing blood pressure (BP \[average of 3 readings\]), and heart rate (HR). Fasting blood samples will be collected daily throughout the hospital stay to ascertain serum laboratory parameters (creatinine, sodium, potassium, and N-terminal pro b-type natriuretic peptide) until achieving a clinically stab...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • acute heart failure;
- • diabetes type 2.
- Exclusion Criteria:
- • low estimated glomerular filtration rate;
- • hypernatremia;
- • diabetes type 1;
- • non-cardiac causes of dyspnea;
- • cardiogenic shock;
- • recent occurrence of Acute Coronary Syndrome;
- • ketoacidosis;
- • hyperosmolar hyperglycemic syndrome.
Trial Officials
Giuseppe Miceli, PhD
Principal Investigator
A.O.U.P. Paolo Giaccone Palermo
About University Of Palermo
The University of Palermo, a distinguished institution located in Italy, is dedicated to advancing medical research and education through innovative clinical trials. Renowned for its commitment to scientific excellence, the university leverages its multidisciplinary expertise and state-of-the-art facilities to conduct research that addresses critical healthcare challenges. By fostering collaborations with leading researchers and healthcare professionals, the University of Palermo aims to translate scientific findings into effective therapies, ultimately contributing to improved patient outcomes and public health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0